Intermittent treatment with FDA-approved drug (rapamycin) that has been shown to extend lifespan in mice may prevent cancer recurrence.

FTA:

Intermittent dosing with rapamycin breaks the inflammatory loop associated with senescence, scientists report. Once disrupted, it takes time for the loop to reestablish itself – providing proof-of-principal that intermittent dosing could provide a way to reap the benefits of rapamycin while bypassing its safety issues. The FDA-approved drug increases healthspan and lifespan in mice.